News ImmuneRegen NewsImmuneRegen BioSciences, Inc. Retains Battelle for Radiation and Infectious Disease TestingSCOTTSDALE, Ariz., Jan. 18 /PRNewswire-FirstCall/ -- ImmuneRegen BioSciences, a wholly owned subsidiary of IR BioSciences Holdings, Inc. (OTC Bulletin Board: IRBO), today announced it has retained Battelle, the world's largest independent research and development organization, as an accredited testing facility. Based in Columbus, Ohio, Battelle will perform laboratory services on ImmuneRegen's behalf on its proprietary compound, Homspera(TM). Battelle currently manages or co-manages five national laboratories for the U.S. Department of Energy. ImmuneRegen plans to utilize Battelle's services immediately to help them perform various studies in support of their two Homspera-based products Viprovex(TM) and Radilex(TM) and to explore additional immunomodulatory properties (e.g., as an adjuvant) in various model systems. These studies could support and expand upon ongoing product development activities. "We are very happy to announce our relationship with Battelle and are excited to have their expertise and welcome their role in helping evaluate our compound as a candidate for therapeutic, prophylactic and adjuvant use against these Threats of the 21st Century -- acute radiation sickness and infectious diseases such as avian influenza, seasonal influenza and anthrax," said ImmuneRegen's CEO Michael Wilhelm. ImmuneRegen's newly hired Senior Director of Product Development and Regulatory Affairs Hal Siegel, Ph.D. added, "Battelle's facilities and demonstrated expertise are a perfect match for our ongoing studies in radiation protection, influenza and anthrax. Their relationships with the National Laboratories and their substantial in-house capabilities provide us with a single contact point for managing our expanding research on the immunomodulatory effects of Homspera in a number of small animal and large animal model systems against different immune challenges and will facilitate the transition into safety studies and non-human primate models as ImmuneRegen moves toward FDA filings later this year." "Battelle looks forward to the opportunity to work with ImmuneRegen BioSciences, Inc. on its exciting new drug candidate," said Michael J. Brooker, Battelle's Vice President. "As drug development becomes more and more challenging, Battelle is constantly assessing new ways to intermix our capabilities into programs that produce the best science possible. The combination of scientists from ImmuneRegen, Oak Ridge National Laboratory, Pacific Northwest National Laboratory and Battelle is unique and will provide the opportunity to create new models to evaluate treatments for both radiation poisoning and infectious disease." Along with maintaining independent laboratory and management facilities worldwide, including world-class toxicology laboratories in Columbus, Ohio and Richland, Washington, Battelle is responsible for managing a number of National Laboratories, including the Pacific Northwest National Laboratory, in Richland, Washington, which is co-located with their private facilities for inhalation studies and radiobiology, as well as significant intellectual resources in these and other specific areas of interest to ImmuneRegen. About Radilex(TM) and Viprovex(TM) About Battelle
About ImmuneRegen BioSciences, Inc.a wholly owned subsidiary of IR BioSciences Holdings, Inc., (OTC BB:IRBS.OB - News) is a development-stage biotechnology company focused on the research, development and licensing of Homspera® and its derivatives. Homspera is an adult stem cell active compound that in study results has been shown to regenerate and strengthen the immune system and enhance wound healing. Viprovex®, a derivative of Homspera, is being developed for potential use against infectious diseases as a stand-alone or combination therapy and as a vaccine adjuvant. To advance its mission, the Scottsdale, Arizona based company has forged numerous study partnerships with industry and academic leaders, including Celgene Cellular Therapeutics, HemoGenix, Lovelace Respiratory Research Institute and Virion Systems. For more information, please visit www.immuneregen.com. Statements about ImmuneRegen's future expectations, including statements about the potential use and scientific results for ImmuneRegen's drug candidates, science and technology, and all other statements in this press release other than historical facts, are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995. ImmuneRegen intends that such forward-looking statements be subject to the safe harbors created thereby. These future events may not occur as and when expected, if at all, and, together with ImmuneRegen's business, are subject to various risks and uncertainties. ImmuneRegen's actual results could differ materially from expected results as a result of a number of factors, including the uncertainties inherent in research and development collaborations, pre-clinical and clinical trials and product development programs (including, but not limited to the fact that future results or research and development efforts may prove less encouraging than current results or cause side effects not observed in current pre-clinical trials), the evaluation of potential opportunities, the level of corporate expenditures and monies available for further studies, capital market conditions, and others set forth in ImmuneRegen's periodic report on Form 10-Q for the three months ended June 30, 2008 and on Form 10-KSB for the year ended December 31, 2007 as filed with the Securities and Exchange Commission. There are no guarantees that any of ImmuneRegen's proposed products will prove to be commercially successful. ImmuneRegen undertakes no duty to update forward-looking statements. Contact: or
### Copyright © 2003-2008, ImmuneRegen Biosciences, Inc. All rights reserved. |
|